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INTRODUCTION
Urinary tract stones are one of  the most prevalent 
urological disorders. It has been estimated that up to 12% 
of the population will suffer from urinary stones during 
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their lifetime, and recurrence rates approach 50% [1]. 
Several treatment methods exist, including observation 
(awaiting spontaneous passage), shock wave lithotripsy 
(SWL), retrograde endoscopic procedures, and percutaneous 
nephrolithotomy. SWL is a safe, effective, noninvasive, and 
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well-established treatment modality, which is now the first-
choice treatment for most upper urinary tract stones [2].
Becoming stone-free after SWL does not occur imme-
diately; instead, the stones are pulverized during the 
procedure, then spontaneously passed through the urinary 
tract. Thus, the time course of  stone clearance varies 
considerably. In most cases, fragmented particles of calculi 
pass uneventfully through the urinary tract after SWL, but 
fragments sometimes obstruct the ureter, causing post-SWL 
complications such as acute renal colic, hydronephrosis, acute 
kidney injury, or urinary tract infection [3]. Particularly for 
larger calculi, a number of stone fragments may become 
impacted in the ureter, forming an obstructing column of 
sand known as steinstrasse. According to the European 
Association of  Urology Urolithiasis Guidelines, ureteral 
stenting reduces the risk of renal colic and obstruction [4], 
and many physicians consider inserting ureteral stents 
before SWL to create an artificial chamber with an impro-
ved stone-fluid interface for better fragmentation during 
SWL and to reduce the risk of obstruction [5]. Accordingly, 
several studies have been performed to determine whether 
routine pre-SWL ureteral stenting is helpful in preventing 
obstructive complications, but the issue remains somewhat 
controversial [6-8]. 
Preventing post-SWL complication is surely important, 
but the ultimate goal of SWL treatment is to establish a 
stone-free status. Similar to the issue of ureteral stenting 
and SWL complications, the effects of SWL on stone-free 
rates (SFRs) are also controversial [7,9,10]. Several recent 
studies have demonstrated that ureteral stenting reduces 
the SFR following SWL [11-13], but the significance of this 
finding is debated. Thus, the current study was conducted 
to evaluate the effects of  ureteral stenting and stone 
characteristics on ureteral stone clearance and to estimate 
the probability of one-session success in SWL patients with 
ureteral calculi according to whether they underwent 
ureteral stenting or exhibited various other factors.
MATERIALS AND METHODS
1. Patient cohort
Medical records were obtained from a database of 
patients (n=1,651) who underwent an initial session of SWL 
between November 2005 and September 2014 at Severance 
Hospital, Seoul, Korea. The study inclusion criteria were 
a single, 4–20 mm, radiopaque calculus located within the 
ureter on plain-film X-rays, presenting within 1 month prior 
to SWL treatment, and without evidence of stone migration. 
Patients with bilateral ureteral stones, urinary tract 
congenital anomalies, or a single kidney, as well as those 
who received prophylactic medical expulsion therapy, were 
excluded from the analysis. This left 680 patients eligible for 
analysis.
2. Good clinical practice protocols
The study was performed in accordance with all 
applicable laws and regulations, good clinical practices, 
and the ethical principles described in the Declaration of 
Helsinki. The Institutional Review Board of  Severance 
Hospital approved this study protocol (approval number: 
4-2015-1052). The study was exempt from requiring the 
participants’ written informed consent because of  its 
retrospective design and because the patients’ records and 
information were anonymized and de-identified prior to 
analysis.
3. Extracorporeal SWL
SWL was performed using an electroconductive 
lithotripter (EDAP Sonolith Praktis, Technomed, Lyon, 
France) until 2011. Beginning in 2012, this was replaced 
by an electromagnetic generative lithotriptor (Dornier 
Compact Delta II lithotripter, Dornier Medtech, Wessling, 
Germany). All ESL procedures were conducted under 
fluoroscopic guidance. The number of  shock waves per 
SWL session varied from 2,500 to 4,000, at a rate of 60–90 
shock waves per minute. We prematurely terminated the 
session if the stone became difficult to visualize during the 
session. The launch intensity was conducted when the focal 
peak pressure ranged from 16 to 55 MPa, as determined 
by the pain reported by the patients while SWL was being 
performed.
4. Demographic data and stone characteristics on 
noncontrast computed tomography
A detailed history of the ureteral stone was obtained, 
including the number of past stone events, history of pain 
onset, and stone characteristics. The stone characteristics 
included the location, maximal stone length (MSL), stone 
heterogeneity index (SHI), skin-to-stone distance (SSD), and 
mean stone density (MSD). The SSD was measured in the 
axial plane, 45o from the vertical axis [14]. The MSL was 
the longest stone length measured in three dimensions on 
noncontrast computed tomography (NCCT) images. We 
used the GE Centricity system (GE Healthcare Bio-Sciences 
Corp., Piscataway, NJ, USA) during the measurement 
procedure. The MSD was measured using bone windows 
on the magniﬁed, axial NCCT image of  the stone in 
the maximal diameter, in which the elliptical region of 
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interest incorporated the largest cross-sectional area of the 
stone without including adjacent soft tissue [15]. The SHI 
was defined as the standard deviation of the Hounsfield 
units (HUs) in the same region of  interest by Lee et al. 
[16]. Complication rate and each variables including post-
SWL complication were also obtained. Successful SWL 
treatment of  the ureteric calculus was deﬁned as the 
patient being rendered stone-free or asymptomatic with 
clinically insigniﬁcant residual fragments ≤3 mm in 
maximal diameter 2 weeks after a single SWL treatment (as 
measured by simple X-ray) [2] and not requiring additional 
treatment within a 3-month follow-up period.
5. Statistical analysis
Data are presented as mean±standard deviation. 
After total cohort analyses, propensity score matching 
was performed to further elucidate the characteristics 
of our patients with ureteral stones. Stenting cases were 
1:6 matched with the closest-propensity stentless cases. 
Propensity scores were then calculated using a multivariable 
logistic regression model with a binomial method based 
on age and MSL (2 factors that demonstrated significant 
differences between the stenting and stentless groups in 
the total cohort) [17]. Propensity score matching can improve 
matching of patients, thereby forming a better comparator 
group. It is a balancing score, wherein the conditional 
distribution of the pretreatment characteristics given the 
propensity score is the same for the case and control groups 
[18]. The propensity score is most commonly estimated via an 
observational study involving patient and other background 
characteristics and using a multivariate logistic regression 
model.
Statistical comparisons of patient demographic continuous 
variables were performed using either a Student or Welch’s 
two-sample t-test. Categorical variables were compared using 
Pearson chi-square test with Yates' continuity correction. 
Univariate and multivariate logistic regression analysis 
using a binomial method were performed to identify factors 
significantly associated with one-session success. Optimal 
cutoff  values for symptom severity were identified from 
Table 1. Demographic data and success rate comparisons between stenting and stentless groups for the total cohort
Variable Total cohort (n=680) Stenting group (n=57) Stentless group (n=623) p-value
Age (y) 52.18±14.33 56.86±14.10 51.75±14.29 0.010a
Sex 0.873b
   Male 442 (65.0) 36 (63.2) 406 (65.2)
   Female 238 (35.0) 21 (36.8) 217 (34.8)
MSL (mm) 9.22±3.92 12.03±6.02 8.96±3.57 <0.001a
SSD (cm) 110.50±19.22 105.90±24.84 110.00±18.58 0.135a
MSD (HU) 708.04±272.19 717.86±285.06 707.14±271.20 0.776a
SHI (HU) 242.22±108.47 237.89±121.75 242.62±107.27 0.753a
Prior stone episodes 0.763b
   FSF 483 (71.0) 39 (68.4) 444 (71.3)
   RSF 197 (29.0) 18 (31.6) 179 (28.7)
Stone location 0.482b
   Upper 554 (81.5) 46 (80.7) 508 (81.5)
   Middle 48 (7.0) 6 (10.5) 42 (6.7)
   Lower 78 (11.5) 5 (8.8) 73 (11.7)
Stone laterality 0.610b
   Right 324 (47.6) 29 (50.9) 295 (47.4)
   Left 356 (52.4) 28 (49.1) 328 (52.6)
Complication rate 25 (3.7) 23 (3.7) 2 (3.5) 1.000
   Pyelonephritis 1 (0.1) 1 (0.2) 0 (0.0)
   Hematuria 2 (0.3) 2 (0.3) 0 (0.0)
   Colic pain 21 (3.1) 19 (3.0) 2 (3.5)
   GI symptoms 1 (0.1) 1 (0.2) 0 (0.0)
One-session success 476 (70.0) 28 (49.1) 448 (71.9) <0.001b
Values are presented as mean±standard deviation or number (%). 
MSL, maximal stone length; SSD, skin-to-stone distance; MSD, mean stone density; SHI, stone heterogeneity index; FSF, first-time stone formers; 
RSF, recurrent stone formers; HU, Hounsfield units.
a:Based on Student or Welch's two-sample t-tests. b:Based on Pearson chi-square tests with Yates' continuity correction.
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the receiver operator characteristic (ROC) curves using 
Youden methods. Statistical analyses were performed 
using R software (ver. 3.0.3, R Foundation for Statistical 
Computing, Vienna, Austria; http://www.r-project.org) and its 
OptimalCutpoints package for optimal cutoff value.
RESULTS
Table 1 lists the baseline characteristics of  the 680 
patients who underwent primary SWL for a single ureteral 
calculus. The overall incidence of  stenting during SWL 
for ureteral calculi was 8.3% (n=57). Comparisons between 
the stenting group and stentless groups based on patient 
and stone NCCT characteristics demonstrated that patient 
age and stone MSL were significantly different between 
the 2 groups. Stenting patients had a significantly longer 
MSL (12.03±6.02 mm in the stenting group, 8.96±3.57 mm 
in the stentless group, p<0.001). There were no significant 
differences between groups for SSD (105.90±24.84 cm in 
the stenting group, 110.00±18.58 cm in the stentless group, 
p=0.135), MSD (717.86±285.06 HU in the stenting group, 
707.14±271.20 HU in the stentless group, p=0.776), and SHI 
(237.89±121.75 HU in the stenting group, 242.62±107.27 in 
the stentless group, p=0.753). The number of previous stone 
episodes, stone location, and stone laterality demonstrated 
no differences between groups. Complication rate and each 
variables including post-SWL complication did not show 
significant differences between 2 groups. One-session success 
was significantly lower in the stenting group: 28 cases (49.1%) 
in the stenting group and 448 cases (71.9%) in the stentless 
group (p<0.001) (Table 1). 
After stenting and stentless cases were 1:6 propensity-
matched, the one-session success rate of the stentless group 
(224 cases, 78.6%) was higher than that of the stenting group 
(28 cases, 49.1%) (p=0.026) (Table 2).
The univariate logistic regression models revealed the 
following predictive factors of one-session success following 
SWL for ureteral stones: shorter MSL (odds ratio [OR], 0.832; 
95% confidence interval [CI], 0.792–0.872; p<0.001), lower MSD 
(OR, 0.997; 95% CI, 0.996–0.998; p<0.001), higher SHI (OR, 
1.003; 95% CI, 1.001–1.005; p<0.001) and absence of a stent (OR, 
0.377; 95% CI, 0.217–0.653; p<0.001). Multivariate analyses 
also demonstrated that a shorter MSL, lower MSD, higher 
SHI, and stentless cases were independent predictors of one-
session success after SWL for ureteral calculi (Table 3).
In stenting cases, one-session failed and success groups 
were divided for subgroup analyses. Between failed 
and success groups in stenting cases, MSL and MSD 
Table 2. Demographic data and success rate comparisons between stenting and stentless groups for the propensity-matched cohort
Variable Total matched cohort (n=399) Stenting group (n=57) Stentless group (n=342) p-value
Age (y) 56.22±13.86 56.86±14.10 56.11±13.84 0.708a
Sex 0.681b
   Male 265 (66.4) 36 (63.2) 229 (67.0)
   Female 134 (33.6) 21 (36.8) 113 (33.0)
MSL (mm) 10.75±4.27 12.03±6.02 10.53±3.88 0.075a
SSD (cm) 110.30±20.25 105.90±24.84 111.50±19.46 0.140a
MSD (HU) 758.14±285.11 717.86±285.06 764.94±284.92 0.250a
SHI (HU) 250.43±116.45 237.89±121.75 250.99±117.80 0.381a
Prior stone episodes 0.763b
   FSF 280 (70.2) 39 (68.4) 241 (70.5)
   RSF 119 (29.8) 18 (31.6) 101 (29.5)
Stone location 0.617b
   Upper 328 (82.2) 46 (80.7) 282 (82.5)
   Middle 30 (7.5) 6 (10.5) 24 (7.0)
   Lower 41 (10.3) 5 (8.8) 36 (10.5)
Stone laterality 0.775b
   Right 196 (49.1) 29 (50.9) 167 (48.8)
   Left 203 (50.8) 28 (49.1) 175 (51.2)
One-session success 252 (63.1) 28 (49.1) 224 (78.6) 0.026b
Values are presented as mean±standard deviation or number (%). 
MSL, maximal stone length; SSD, skin-to-stone distance; MSD, mean stone density; SHI, stone heterogeneity index; FSF, first-time stone formers; 
RSF, recurrent stone formers; HU, Hounsfield units.
a:Based on Student or Welch's two-sample t-tests. b:Based on Pearson chi-square tests with Yates' continuity correction.
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demonstrated the significant differences (Table 4). For one-
session success rates, the area under the curve (AUC) of 
ROC curves was 0.689 (95% CI, 0.635–0.742) for MSL and 0.686 
(95% CI, 0.632–0.740) for MSD. The cutoff values for MSL 
and MSD were 10.0 mm and 784 HU, respectively. As shown 
in Table 5, the number of patients with one-session success 
status was higher in the stentless group than in the stenting 
group for patients with an MSL >10 mm (p=0.002) or an 
MSD ≤784 HU (p=0.001).
Table 3. Univariate and multivariate logistic regression models for predictive factors of one-session success following shock wave lithotripsy for 
ureteral stones
Parameter Odds ratio 95% CI p-value
Univariate
   Age 1.006 0.995–1.018 0.275
   Male sex 0.793 0.557–1.122 0.195
   MSL 0.832 0.792–0.872 <0.001
   MSD 0.997 0.996–0.998 <0.001
   SSD 1.001 0.992–1.010 0.799
   SHI 1.003 1.001–1.005 <0.001
   Recurrent stone formers 1.152 0.802–1.670 0.452
   Stone location (%)
      Upper Reference
      Middle 0.683 0.373–1.281 0.222
      Lower 0.868 0.527–1.466 0.588
   Laterality, right 1.204 0.866–1.674 0.269
   Stenting 0.377 0.217–0.653 <0.001
Multivariate
   MSL 0.901 0.854–0.948 <0.001
   MSD 0.996 0.994–0.997 <0.001
   SHI 1.010 1.007–1.012 <0.001
   Stenting 0.432 0.217–0.863 0.017
CI, confidence interval; MSL, maximal stone length; MSD, mean stone density; SSD, skin-to-stone distance; SHI, stone heterogeneity index.
Table 4. Demographic and factor comparisons between failed and success groups in stenting patients
Variable Failed group (n=29) Success group (n=28) p-value
Age (y) 57.90±12.59 55.79±15.67 0.577a
Sex 1.000b
   Male 18 (62.1) 18 (64.3)
   Female 11 (37.9) 10 (35.7)
MSL (mm) 13.54±6.25 10.46±5.45 0.052a
SSD (cm) 108.39±26.24 103.24±23.49 0.438a
MSD (HU) 809.56±326.92 622.89±198.31 0.012a
SHI (HU) 225.28±121.47 250.96±122.85 0.431a
Stone location 0.202b
   Upper 25 (86.2) 21 (75.0)
   Middle 1 (3.4) 5 (17.9)
   Lower 3 (10.3) 2 (7.1)
Stone laterality 0.144b
   Right 12 (41.4) 17 (58.6)
   Left 17 (58.6) 11 (39.3)
Values are presented as mean±standard deviation or number (%). 
MSL, maximal stone length; SSD, skin-to-stone distance; MSD, mean stone density; SHI, stone heterogeneity index; HU, Hounsfield units.
a:Based on Student or Welch's two-sample t-tests. b:Based on Pearson chi-square tests with Yates' continuity correction.
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DISCUSSION
Since the introduction of  ureteroscopy, SWL, and 
percutaneous nephrolithotomy, researchers have expended 
much effort to determine the factors associated with 
high success and low complication rates in the treatment 
of  urinary stone disease. For SWL, factors reported to 
influence success and complication rates include the stone 
size, composition, density, and location; total number and 
frequency of shock waves; operators’ experience; and type 
of  lithotripter. Pre-SWL ureteral stenting has also been 
proposed as an important way to reduce complications 
following SWL. 
A primary rationale for performing ureteral stenting is 
to prevent complications associated with ureteral obstruction 
as stone fragments pass down the ureter. Several previous 
studies investigated the ef f icacy of  ureteral stent in 
preventing these complications. Mohayuddin et al. [19] 
reported that steinstrasse and fever were not affected by 
whether or not a ureteral stent was used, but ureteral colic 
was significantly lower in their ureteral stenting group. In 
a prospective randomized clinical trial, the ureteral stenting 
group exhibited lower rates of  hospital readmission and 
Emergency Department visits, and 13% of  the stentless 
group but only 2% of the stenting group had steinstrasse 
formation [10]. In a recent meta-analysis, the authors noted 
that the steinstrasse rate was significantly lower in the 
stenting group, whereas fever, urinary tract infection, pain, 
and auxiliary treatment did not differ between groups [7]. 
From these results about post-SWL complications, the effects 
of ureteral stent for passage of fragments during SWL seem 
to be controversial.
Until now, reducing complications following SWL has 
been one of the most important goals of SWL for urinary 
stone management, although achieving stone-free status 
is the ultimate objective. Unfortunately, few reports have 
indicated that ureteral stents increase stone-free status 
or success rates following SWL. Several previous studies 
demonstrated that ureteral stents do not improve SWL 
success or SFR [9,10,19-21]. Rather, recent studies found that 
ureteral stents negatively affect SWL success or SFR. For 
example, Pettenati et al. [12] demonstrated that the presence 
of a ureteral stent negatively affects the efficacy of SWL in 
treating lumbar ureteral stones These authors found that 
the success rate with stenting was significant lower than 
the rate without stenting in patients with stones larger 
than 8 mm. Ozkan et al. [13] also reported that SFR was 
significantly higher in their stentless group than in their 
stenting group. Furthermore, in 2 randomized controlled 
trials, ureteral stenting was found to reduce the SFR [11], 
and the absence of  an indwelling ureteral stent was an 
independent predictor of success [22]. 
Our results were similar to those of previous studies, 
supporting the negative effects of ureteral stenting on SFR. 
Although MSL, which can affect SFR, differed significantly 
between the stenting and stentless groups in our total 
cohort, the presence of  a ureteral stent was the only 
factor that differed significantly between groups after 1:6 
propensity score matching. The negative effects of stenting 
may be explained by 2 theories, which are not mutually 
exclusive. First, in order to have a maximal effect, shock 
waves must impinge on a stone surrounded by liquid. The 
ureteral stent may absorb some of the energy created by 
the shock waves, thus reducing their effect on the stones [9]. 
Table 5. Comparison of stone-free status in stenting and stentless group according to optimal cutoff value for MSD and MSL
Variable Stenting group Stentless group p-valuea
MSD > 784 HU
   Total 21 205
   One-session success 6 (28.6) 99 (48.3) 0.135
MSD ≤ 784 HU
   Total 36 418
   One-session success 22 (61.1) 349 (83.5) 0.001
MSL > 10 mm
   Total 28 178
   One-session success 8 (28.6) 93 (52.2) 0.002
MSL ≤ 10 mm
   Total 29 449
   One-session success 20 (69.0) 355 (79.1) 0.294
Values are presented as number or number (%). 
MSD, mean stone density; MSL, maximal stone length; HU, Hounsfield units.
a:Pearson chi-square test with Yates' continuity correction.
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Second, the presence of a ureteral stent may cause ureteral 
edema, thus interrupting the passage of stone fragments [23-
25]. The impact would be greater with ureteral stones than 
renal stones because the area of contact between the stone 
and stent would be larger and ureteral edema would have 
a greater effect on ureteral stones. Very few studies have 
distinguished between renal stones and ureteral stones.
Based on our findings and results of previous studies, 
pre-SWL ureteral stenting does not appear to have definite 
advantages in terms of SFR or complications, compared to in 
situ SWL. In addition, the decision to proceed with ureteral 
stenting requires much caution because it is a relatively 
invasive procedure. Furthermore, we should also consider the 
possibility of stent-related voiding symptoms, such as bladder 
irritation symptoms and flank pain or discomfort [26,27]. In 
their randomized control study, Ghoneim et al. [9] noted that 
microscopic hematuria, pyuria, dysuria, and suprapubic pain 
were significantly more common in patients with a ureteral 
stent than in those without. Another study, by El-Assmy et 
al. [20], of patients with ureteral stones 2 cm or less causing 
moderate or severe obstruction also showed that the rates 
of post-SWL morbidities related to ureteral stents (such as 
suprapubic pain, gross or microscopic hematuria, pyuria, 
and positive urine cultures) were significantly higher 
in their ureteral stenting group. Thus, we recommend 
against routine pre-SWL ureteral stenting; instead, ureteral 
stents should be reserved for special indications, such as 
complicated urinary tract infection or severe pain.
A unique aspect of  our study is that we calculated 
the AUC and cutoff values for MSL and MSD, and then 
analyzed the SWL success rates according to the presence 
of a stent in subgroups based on these cutoff values. Since 
NCCT was introduced in the management of urinary tract 
stone disease, MSL and MSD have been widely recognized as 
predictors of SWL success rate [15,28-30]. In our multivariate 
logistic regression analysis, a shorter MSL, lower MSD, 
and absence of  a stent were positive predictors for one-
session success in patients who underwent SWL, which is 
consistent with the results of previous studies. The AUCs 
for MSL and MSD were high (0.689 and 0.686, respectively), 
compared to the AUCs for other factors. The cutoff values 
for MSL and MSD were 10.0 mm and 784 HU, respectively. 
When we analyzed the success rate of subgroups based on 
these cutoff values, the results for MSL were interestingly 
contrary to those observed for MSD. In patients with an 
MSL>10 mm, the success rate was significantly lower in 
the stenting group, but in those with an MSL≤10 mm, there 
was no difference in success rate between the 2 groups. 
These findings are similar to those of Pettenati et al. [12], in 
which SWL success was lower in the stenting group only 
with larger stones, defined as a size >8 mm. The differential 
effects of  MSL may be explained to some degree by the 
theories mentioned above. Larger stones have a wider area 
of contact between the stone and stent, which presumably 
leads to greater energy absorption by the stent, thus 
increasing the likelihood of impaired stone fragmentation. 
By contrast, the success rate was higher in the stentless 
group than in the stent group in patients with a lower MSD 
(≤784 HU), representing a more fragile stone. If  a stone 
is fragile, the stent can play a more significant role as an 
interference factor, thus promoting treatment failure. 
Our results thus suggest that when physicians are 
deciding whether to perform ureteral stent insertion 
before SWL, they may consider MSL and MSD as factors 
influencing SWL failure (although further study is required 
to more definitively address this issue). In patients with a 
ureteral stone with a low MSD and large size, the decision to 
perform pre-SWL stenting should be based on symptoms and 
renal function of the patient. In addition, when physicians 
are trying to choose between treatment options, including 
retrograde ureteroscopic surgery and SWL, our overall 
higher one-session success rates with stones exhibiting a 
lower MSD and lower MSL (including both the stenting and 
stentless groups) suggest that it may be more appropriate to 
perform surgery in patients with stones with a high MSD 
and large volume.
This study has some inherent limitations because of its 
retrospective design, which may have introduced sampling 
bias; however, we used a relatively large cohort of patients 
undergoing SWL for ureteric stones. In addition, to overcome 
this type of limitation and elucidate the impact of MSL and 
MSD on SWL outcomes more clearly, we limited the study 
to include subjects who had only ureteric stones. With renal 
stones, anatomical considerations including the location 
of calyx and renal pelvic stones or the infundibulopelvic 
angle can be another source of bias. Furthermore, we could 
not analyze the reasons for stenting due to retrospective 
design. This may work as a significant bias because renal 
function or hydronephrosis grade which acts main causes 
of prestenting can be impact factors of SWL success rate. 
The 2 different lithotripsy machines may be a source of 
bias, but there were no statistical differences between the 
2 time periods (data not shown). Despite these limitations, 
the study has certain strengths, including our focus on the 
results of SFR as a more important goal than complication 
rates and our analysis of one-session success rates following 
SWL according to stone characteristics (MSL and MSD) 
in relation to the presence of a stent. In the future, large 
415Investig Clin Urol 2016;57:408-416. www.icurology.org
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prospective studies are needed to confirm our observations 
on the negative effect of ureteral stenting on SFR.
CONCLUSIONS
Ureteral stenting during SWL was a negative predictive 
factor for one-session success in patients with a single 
ureteral stone. Furthermore, in patients with stones that 
exhibited a lower MSD and higher MSL, ureteral stenting 
negatively influenced one-session outcomes, compared to 
SWL without stenting.
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